



Katherine Eban

Author, *Bottle of Lies: The Inside Story of the Generic Drug Boom*

Katherine Eban, an investigative journalist, is a *Fortune* magazine contributor and Andrew Carnegie fellow. Her articles on pharmaceutical counterfeiting, gun trafficking, and coercive interrogations by the CIA, have won international attention and numerous awards. She lectures frequently on the topic of pharmaceutical integrity. *Bottle of Lies: The Inside Story of the Generic Drug Boom*, her second book, is a *New York Times* bestseller and was published by Ecco/HarperCollins in May. Based on a decade of reporting, the book reveals endemic fraud and dire conditions in the overseas manufacturing plants where the majority of our low-cost generic medicine is made. Educated at Brown University and Oxford, where she was a Rhodes Scholar, Eban lives in Brooklyn with her husband, two daughters and Newfoundland dog Romeo.

Questions for Panelist

- What health products or services are Chinese firms providing in the United States, and how have these products/services changed over the last 5 years?
- What genomic research have Chinese entities provided to U.S. companies or individuals? What concerns, if any, should policy makers have regarding these activities?
- Do Chinese government regulations managing the production and export of health products and medicines sufficiently address potential public health concerns?
- What are the trends and implications of Chinese investment in the U.S. health, biotech, and pharmaceutical industries?
- How do Chinese investments, cooperative research ventures, intellectual property theft, and other activities in health and pharmaceutical industries advance China's interests, and do they present a threat to U.S. economic or national security interests?
- What are Chinese biotechnology firms' activities in the United States, and do these activities pose data privacy or other national security risks?
- What specific sourcing vulnerabilities exist for private U.S. medical facilities, patients, and consumers vis-à-vis Chinese medical and biotech companies?
- Is the U.S. government adequately equipped to address risks to U.S. public health or national security posed by China's role in medical, pharmaceutical, and biotech supply chains?
- The Commission is mandated to make policy recommendations to Congress based on its hearings and other research. What are your recommendations for Congressional action related to the topic of your testimony?